Corpus Intelligence IC Memo — KFH - SANTA ROSA 2026-04-26 04:04 UTC
IC Memo — KFH - SANTA ROSA
Investment Committee Memorandum | CA | 172 beds | Grade C | EBITDA uplift $33.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KFH - SANTA ROSA

CCN 050690 | SONOMA, CA | 172 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

KFH - SANTA ROSA is a 172-bed suburban community hospital in SONOMA, CA with $458.9M in net patient revenue and a 0.4% operating margin. The hospital serves a payer mix of 2.6% Medicare, 6.6% Medicaid, and 90.8% commercial.

Thesis: Undervalued. Our ML models identify $33.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.4% to 7.8% (+736bps).

Net Revenue HCRIS$458.9M
Current EBITDA COMPUTED$1.9M
Operating Margin COMPUTED0.4%
Occupancy HCRIS71.0%
Revenue / Bed COMPUTED$2.7M
Net-to-Gross HCRIS28.2%
Distress Probability ML40.8%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
209
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 0.4% places it above the state median. Among 209 size-comparable peers (86-344 beds), the median margin is -4.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (86-344), prioritizing same-state peers. 209 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KFH - SANTA ROSA (Target)CA172$458.9M0.4%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KFH - SANTA CLARACA343$1.25B12.5%
KECK HOSPITAL OF USCCA301$1.11B-20.8%
SUTTER ROSEVILLE MEDICAL CENTECA318$1.07B12.1%
CALIFORNIA PACIFIC MEDICAL CENCA274$987.8M-18.5%
ZUCKERBERG SAN FRANCISCO GENERCA284$889.5M-41.7%
SANTA MONICA UCLA MEDICAL CENTCA281$835.9M2.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $33.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.6M+210bp18mo
Cost to Collect4.5%2.5%$9.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.6M+122bp9mo
Clean Claim Rate88.0%96.0%$294K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.6M
Cost to Collect
$9.2M
Denial Rate Reduction
$9.1M
A/R Days Reduction
$5.6M
Clean Claim Rate
$294K
Total EBITDA Uplift$33.8M
Current EBITDA$1.9M
+ RCM Uplift+$33.8M
Pro Forma EBITDA$35.7M
Current Margin0.4%
Pro Forma Margin7.8%
WC Released (1x)$17.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.9M$350.2M121.08x161.0%
Base (11x exit)10.0x11.0x$2.9M$386.1M133.51x166.1%
Bull Case9.0x11.0x$2.6M$498.5M191.53x186.1%
Bull (12x exit)9.0x12.0x$2.6M$544.6M209.23x191.2%
Bear Case11.0x10.0x$3.2M$180.3M56.69x124.2%
Bear (11x exit)11.0x11.0x$3.2M$199.4M62.68x128.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 209 hospitals with 86-344 beds
  • Same-state prioritization (n=210)
  • Comp margins: P25=-17.7% / P50=-4.6% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.